Skip to main content
. 2011 Jun 15;7(3):282–292. doi: 10.5664/JCSM.1074

Figure 2.

Figure 2

Mean (SD) change from baseline in IRLS total score by visit (mITT population)

Adjusted mean treatment difference GEn compared with placebo at Week 12 LOCF: Co-primary endpoint: GEn 1200 mg, −3.5 (95% CI: −5.6, −1.3; p = 0.0015); Secondary endpoint: GEn 600 mg, −4.3 (95% CI: −6.4, −2.3; p < 0.0001). ***p < 0.0001; **p < 0.001; *p < 0.01. CI, confidence interval; GEn, gabapentin enacarbil; IRLS, International Restless Legs Scale; LOCF, last observation carried forward; mITT, modified intent-to-treat; PBO, placebo; SD, standard deviation. Mean (SD) change from baseline in IRLS total score over time using last observation carried forward was similar to the observed case data.